Navigation Links
Molecule May Trigger Psoriasis
Date:1/18/2008

Study in mice offers hope for new treatment of chronic skin disease

FRIDAY, Jan. 18 (HealthDay News) -- A molecule may play a major role in the development of psoriasis, offering a new way to treat this chronic skin disease, a study finds.

A team at Wyeth Research, in Cambridge, Mass., found that antibodies that neutralized the IL-22 molecule in mice prevented the development of psoriasis-like lesions. The researchers also found injecting IL-22 into the skin of normal mice activated genes associated with the development of psoriasis-like skin lesions.

These findings, published in the Jan. 17 issue of the Journal of Clinical Investigation, suggest that targeting IL-22 may provide a new approach to treating people with psoriasis, the study authors said.

Psoriasis, which causes red, scaly, raised skin lesions, affects up to 3 percent of the world's population and more than 7.5 million Americans, according to the National Psoriasis Association.

More information

The U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases has more about psoriasis.



-- Robert Preidt



SOURCE: Journal of Clinical Investigation, news release, Jan. 17, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1

Related medicine news :

1. Alzheimers molecule is a smart speed bump on the nerve-cell transport highway
2. Molecules might identify high-risk acute-leukemia patients
3. Common molecule notifies immune system of prostate cancer
4. Tiny RNA Molecules Control Breast Cancers Spread
5. Molecules can block breast cancers ability to spread
6. Major Advance in the Observation of DNA Molecules
7. St. Jude finds molecule that could improve cancer vaccines and therapy for other diseases
8. Jefferson neuroscientists show anti-inflammation molecule helps fight MS-like disease
9. Researchers identify molecules with interesting anti-clotting properties
10. Study Describes Molecules That Control Blood Pressure
11. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Molecule May Trigger Psoriasis
(Date:5/26/2017)... , ... May 26, 2017 , ... “When the Stars ... Home” is the creation of published author Laura Weigel Douglas, an avid reader who ... in a house that sometimes feels like Green Hills Adventure Camp. She couldn’t be ...
(Date:5/26/2017)... ... 2017 , ... Centennial-based BluSky Restoration Contractors announced that The ... Clays for Kids fundraiser, to be held Friday, Sept. 22, at Kiowa Creek ... of BluSky’s partnership with The Adoption Exchange, BluSky will also share sponsorship with ...
(Date:5/26/2017)... , ... May 26, 2017 , ... “Cactus Jack: Against ... on so many others. “Cactus Jack: Against All Odds” is the creation of ... Walter D. Hubbard is married to Jack Carlisle’s third child Jane. Walter. Walter ...
(Date:5/24/2017)... ... May 24, 2017 , ... Last month, representatives from ... employees, and town officials to celebrate the grand opening of the 87,000 square ... as part of its ongoing relationship with RWJBarnabas Health, New Jersey’s largest health ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Alan I. Benvenisty, MD is dual board ... He is known for his distinguished expertise and experience in the diagnosis and treatment ... training in treating renovascular disease and aortic aneurysm . He is known for ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)... 2017  As the specialty pharmacy industry and ... make the revolutionary shift from volume-based to value-based ... positive patient outcomes and shaping the future of ... away from clinical trials and toward data that ... drug therapy utilization in precise patient populations. Therigy ...
(Date:5/15/2017)... , May 15, 2017 Enterin Inc., a ... and developing novel compounds to treat Parkinson,s disease (PD), ... study is a Phase 1/2a randomized, controlled, multicenter study involving ... It will enroll 50 patients over a 9-to-12-month period. The ... in 10 patients with PD. Participating sites include ...
(Date:5/10/2017)... May 10, 2017 Global Health Intelligence ... Latin America , published its 2017 ranking of the ... based on extensive data analysis from GHI,s hospitals database ... database for the region. The GHI database covers 86% of ... more than 130 data points for each institution in key ...
Breaking Medicine Technology: